Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements
Eagle Pharmaceuticals (OTCMKTS: EGRX) announced on Oct 15, 2025 that its unaudited financial statements for the three and six months ended June 30, 2025 are available for investors.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Eagle Pharmaceuticals (OTCMKTS: EGRX) announced on Oct 15, 2025 that its unaudited financial statements for the three and six months ended June 30, 2025 are available for investors.
The statements can be accessed via the company’s investor relations page at https://investor.eagleus.com/events-presentations.
Details
News Market Reaction – EGRX
On Oct 20, the first trading day after this news, EGRX closed 14.00% below the previous close.
Data tracked by StockTitan Argus for the Oct 20 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WOODCLIFF LAKE, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company’s unaudited financial statements for the three and six months ended June 30, 2025, are available at https://investor.eagleus.com/events-presentations.
About Eagle Pharmaceuticals, Inc.
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® and BARHEMSYS® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states, and the company is focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. Additional information is available on Eagle’s website at www.eagleus.com.
Investor Relations Contact
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.